Costs of First-Line Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With Covalent Bruton Tyrosine Kinase Inhibitors: Simulation of the Impact of the Inflation Reduction Act
Background
Covalent Bruton tyrosine kinase inhibitors (cBTKis) are standard of care for first-line (1L) treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). Per the Inflation Reduction Act (IRA) Drug Price Negotiations (DPN), ibrutinib became the first cBTKi with a negotiated maximum fair price (MFP) in Initial Price Applicability Year (IPAY) 2026. Estimating the potential IRA pricing impact on total cost of care for patients treated with cBTKis is critical to inform payer and pathway decision-making.
This study aimed to compare total health care costs and CLL/SLL-related pharmacy costs for patients with CLL/SLL receiving 1L ibrutinib vs other cBTKis (acalabrutinib or zanubrutinib) post IRA price reduction and MFP effectuation for ibrutinib.
Methods
This retrospective cohort study used administrative health claims data from Optum Clinformatics Data Mart (January 1, 2012-December 31, 2024) to identify adults with CLL/SLL who initiated 1L monotherapywith ibrutinib or other cBTKis on or after November 21, 2019, the date of acalbrutinib approval). Costs (2024 USD) were assessed from index (start of 1L) until end of 1L, death, or data cutoff. Outcomes were analyzed overall and in cohorts by insurance type (commercial or Medicare). Overlap-weighted adjusted regression models were used to estimate mean per-patient-per-month (PPPM) cost differences with bootstrapped 95% CIs. Based on Wholesale Acquisition Cost mirroring of the published 38% price reduction per the IRA MFP, a 41% ibrutinib price reduction was applied to simulate costs post-MFP effectuation, holding all other parameters constant.
Results
A total of 2097 patients were included (commercial, n = 228 [ibrutinib, n = 99; other cBTKis, n = 129]; Medicare, n = 1869 [ibrutinib, n = 668; other cBTKis, n = 1201]). Cohorts were well balanced after weighting. Post-MFP effectuation, a 41% price reduction for ibrutinib is expected to result in cost savings with ibrutinib vs other cBTKis. For total health care costs, the projected mean (95% CI) cost saving with ibrutinib vs other cBTKis was $3448 (−$488to $6386; P = 0.09) in commercial patients, $3594 ($2412 to $4635; P < 0.001) in Medicare patients, and $3456 ($2492 to $4412; P < 0.001) in the overall sample. For CLL/SLL-related pharmacy costs, the projected mean (95% CI) cost saving with ibrutinib vs other cBTKis was $4801 ($3548 to $5905; P < 0.001) in commercial patients, $4239 ($3788 to $4695; P < 0.001) in Medicare patients, and $4271 ($3823 to $4677; P < 0.001) in the overall sample.
Author Information
Authors:
Bhavini Srivastava, MSc1; Bruno Emond, MSc2; Shaffee Bacchus, PharmD1; Alyssa Davis, PharmD1; Jessica Maitland, MSc3; Erin Franceschini, MS1; Elizabeth Hore, PhD4; Gordon Wong, BIE2; Shirley Zhu, MPH2; Kavita Sail, PhD1
Affiliations:
1AbbVie, Inc; 2Analysis Group, Ltd; 3Analysis Group ULC; 4Analysis Group, Inc
Sponsor:
This study was funded by AbbVie.


